Bayer to Divest 3.6% Stake to Singapore Company Temasek

Bayer AG BAYRY will divest its 3.6% stake to Singapore's state investment company Temasekfor total gross proceeds of €3 billion. Along with its existing holding in Bayer, Temasek will own about 4% in Bayer after the transaction. Bayer has announced the deal toward its planned $66 billion takeover of Monsanto MON.

Per the deal, Bayer will issue to a subsidiary of Temasek at an at-market price the new registered (no-par value) shares with an entitlement to dividends as of Jan 1, 2017.

Bayer stated that the proceeds from the placement would be taken into account when settling the size of the previously announced rights issue to fund the Monsanto takeover. Shares issued to Temasek will not be subject to any lock-up period. 

This investment is in sync with Bayer’s business strategy including the proposed acquisition of Monsanto, as well as Bayer’s strong growth prospects.

Shares of Bayer have returned 12.1% compared with the industry’s gain of 8.8% over a year.

We remind investors that in October 2017, Bayer signed an agreement to sell selected Crop Science businesses to BASF for €5.9 billion, in light of the planned acquisition of Monsanto Company. The Brazilian antitrust authorities approved the acquisition.  The company also committed to divest its entire vegetable seed business. Certain additional business activities of Bayer and Monsanto may also be sold or out-licensed.

The latest transaction is subject to regulatory approval as well as the successful closing of Bayer’s acquisition of Monsanto. Meanwhile, Bayer will continue to own, operate and maintain these businesses until the closing of this divestiture.

 

Bayer Aktiengesellschaft Price

 

Bayer Aktiengesellschaft Price | Bayer Aktiengesellschaft Quote

Zacks Rank and Stocks to Consider

Bayer carries a Zacks Rank #4 (Sell).

A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals LGND andProtagonist Therapeutics PTGX. Both of them sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Ligand’s earnings per share estimates have moved up $3.78 to $4.40 from $4.75 to $5.32 for 2018 and 2019, respectively, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 62.8% over a year.

Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.

 

Can Hackers Put Money INTO Your Portfolio?

Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.

Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.

Download the new report now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
 
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
 
Monsanto Company (MON) : Free Stock Analysis Report
 
Protagonist Therapeutics, Inc. (PTGX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research